Clinical trials on medicinal products - Pandemic by SARS-CoV-2

Recommendations Swissmedic / swissethics for the treatment of patients - update

05.11.2020

The spread of the new coronavirus (SARS-CoV-2) also poses a major challenge for clinical trials of medicinal products in Switzerland.
Swissmedic and swissethics have therefore published a joint document, which describes the most important recommendations for the treatment of patients in clinical trials of medicinal products.

Due to the current situation, changes were introduced in the submission process for reportings / applications in the framework of clinical trials with medicinal drug products. Details related to the amended submission process are outlined in the guidance paper.